Guggenheim Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $68

Janux Therapeutics (JANX) dosed the first patient in a Phase 1 trial for JANX013, a treatment for metastatic castration-resistant prostate cancer (mCRPC), in combination with JANX007. The study will evaluate safety, tolerability, and preliminary efficacy. JANX013 aims to enhance anti-tumor immune responses. JANX stock is up 1.81% at $17.41.

Analysts upgraded four companies: Baird raised Darden (DRI) to Outperform with a $250 target, Wolfe upgraded Janux (JANX) to Outperform with a $23 target, UBS upgraded Celestica (CLS) to Buy with a $430 target, and Wolfe upgraded PulteGroup (PHM) to Outperform with a $129 target. All companies closed at or near their respective targets on Friday.

Janux Therapeutics, Inc. (JANX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights • JANX007 Phase 1b enrollment continues across taxane-naïve monotherapy and darolutamide combination cohorts • JANX014 Phase 1 study continues enrolling patients with metastatic

NVIDIA is investing in both proprietary and open-source AI models, including a $90M Series B round for Nous Research, valuing it at $1.5B. Nous claims its Hermes 4.3 model outperforms GPT-4o in key metrics, but lacks independent verification. The company aims to compete with lower pricing, offering $0.30 per million tokens compared to competitors' higher rates. NVIDIA's strategy ensures its hardware remains central to AI infrastructure regardless of the winning model architecture.

Piper Sandler initiated coverage of LCNB Corp. with a Neutral rating and $20 price target, citing its lower-cost funding, revenue diversity, and regional scarcity. The target is based on 11x 2027 EPS, a premium to peers. LCNB has a P/E of 10.98, a 4.71% dividend yield, and steady loan growth prospects of 2% in 2027, according to Piper Sandler.

Biohaven (BHVN) has licensed its IgG degrader portfolio to Ono Pharma for Asian markets, including Japan and South Korea. The deal includes up to $100M in payments, with Biohaven retaining rights outside these regions. The portfolio, led by BHV-1300 in Phase 3 trials for Graves' disease, aims to treat autoimmune disorders. Biohaven's stock closed at $11.88, up 1.18% in pre-market trading.